USA / Rare Disease Strategies in a Booming Market
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of innovation, access,…
Address: 7500 Security Boulevard, Baltimore, MD 21244
Tel: -3376
Web: http://www.cms.gov/
The Medicare and Medicaid programs were signed into law on July 30, 1965. President LBJ is pictured at the signing ceremony in Independence, Missouri at the Truman Library. Former President Truman is seated beside him. LBJ held the ceremony there to honor President Truman’s leadership on health insurance, which he first proposed in 1945. You can read LBJ’s speech at the signing ceremony and listen to his taped conversations relating to CMS programs. Key speeches and press conference excerpts from other President’s are also available. See the links in the Downloads section below.
The most significant legislative change to Medicare–called the Medicare Modernization Act or MMA–was signed into law by another President from Texas, George W. Bush, on December 8, 2003. This historic legislation adds an outpatient prescription drug benefit to Medicare and makes many other important changes. You can read his speech at the signing ceremony and see pictures of the event at the White House web site. See the links in the Downloads and Related Links Outside CMS sections below.
Oral histories of former Secretaries, Administrators, Members of Congress and other important players in the history of CMS programs are available as well as more oral histories and other CMS related-materials on the SSA web page. See the links in the Downloads and Related Links Outside CMS sections below.
Since 1965, a number of changes have been made to CMS programs. A more detailed listing of those changes is at CMS milestones. Moreover, the agencies charged with implementing the programs have changed as well. See agency history for more information about Medicare’s early days in Social Security, Medicaid’s early days in the Social and Rehabilitative Services Administration, and why they were joined together into one agency in 1977. Learn why CMS headquarters is located in Baltimore County, Maryland and how it was almost moved to the City of Baltimore. See the links in the Downloads and Related Links Outside CMS sections below.
The Centers for Medicare & Medicaid Services (CMS) ten Field offices reorganized in February 2007 moving from a geography-based structure to a Consortia structure based on the Agency’s key lines of business: Medicare health plans, Medicare financial management, Medicare fee for service operations, Medicaid and children’s health, survey & certification and quality improvement. The intent of the new structure is to improve performance through uniform issue management, consistent communication and leadership focused on achieving the Agency’s strategic action plan. Over the past year, the Field has made progress in these areas and more.
Medicare, Medicaid/CHIP, Medicare-Medicaid Coordination, Insurance Oversight, Innovation Center, Regulations and Guidance Research, Statistics, Data and Systems, Outreach and Education
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of innovation, access,…
With a series of reorganization initiatives, new leaders at the helm and exciting acquisitions, Novartis Oncology has undergone a significant business transformation in the past few years, and if the…
Joe Lewis outlines the key concerns of Deloitte’s pharma clients around manufacturing and supply chain operations in the wake of the COVID-19 pandemic, how companies can come out of the…
After five years with Takeda heading up the Japan-headquartered pharma company’s US business, following the organization’s 2019 USD 62 billion acquisition of US rare disease player Shire, Ramona Sequeira was…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability. The life sciences industry within the United States makes significant contributions to…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory Committee’s meeting on November 6 2020,…
Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain political capital despite massive and proven flaws.…
Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded to the COVID-19 pandemic and the solutions that PhRMA…
Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into rare diseases, product launch strategies, access and affordability issues, and…
Brent Ragans of Ferring Pharmaceuticals US discusses the effects of the COVID-19 pandemic on the company’s operations, their footprint in reproductive health and Crohn’s Disease, virtual product launches and digitalisation,…
Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a wide range of patient groups, increasing…
Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in culture, and the company’s multifaceted response to the COVID-19 crisis.…
See our Cookie Privacy Policy Here